Progyny (NASDAQ:PGNY) Issues FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 1.830-1.950 for the period, compared to the consensus EPS estimate of 1.550. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q1 2026 guidance to 0.420-0.450 EPS.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PGNY. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research note on Tuesday, January 20th. Barclays initiated coverage on Progyny in a research note on Monday, December 8th. They issued an “overweight” rating and a $29.00 price target for the company. Weiss Ratings restated a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Finally, Zacks Research lowered Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Progyny currently has an average rating of “Moderate Buy” and a consensus target price of $29.80.

Progyny Trading Down 22.2%

Progyny stock traded down $4.95 during midday trading on Friday, reaching $17.30. The company’s stock had a trading volume of 894,431 shares, compared to its average volume of 1,406,444. The stock has a market cap of $1.49 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 1.35 and a beta of 0.96. Progyny has a 52 week low of $17.27 and a 52 week high of $28.75. The business has a 50-day moving average price of $24.08 and a 200-day moving average price of $23.13.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, research analysts predict that Progyny will post 0.6 EPS for the current fiscal year.

Progyny News Roundup

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q4 beat — Progyny reported better-than-expected Q4 results, with EPS of $0.48 vs. consensus ~$0.38 and revenue of $318.4M (up 6.7% year/year). This confirms underlying operating strength. Zacks: Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised EPS outlook — Progyny raised FY‑2026 EPS guidance to $1.83–$1.95 (well above prior consensus) and gave Q1 EPS guidance above Street expectations, supporting margin/earnings confidence. GlobeNewswire: Q4 Results
• Positive Sentiment: Cash flow and buybacks — Company generated a record $210.2M in operating cash flow for the year and has repurchased roughly 6.5M shares to date, which is shareholder‑friendly and supports per‑share metrics. GlobeNewswire: Q4 Results
• Neutral Sentiment: Earnings call details available — Management expanded on strategy and growth drivers in the earnings call/transcripts; these provide color but did not materially change the mixed headline view. Yahoo Finance: Q4 Earnings Call Highlights
• Neutral Sentiment: Longer-term growth track record — Company noted its tenth consecutive year of revenue growth, which supports the secular thesis but may be insufficient to offset near-term guidance worries for some investors. GlobeNewswire: Q4 Results
• Negative Sentiment: Soft near‑term revenue guidance — Q1 revenue guidance was set at $319M–$332M, well below consensus (~$345M), and FY revenue guidance was roughly flat to Street expectations; the weaker revenue outlook is the primary driver of downward pressure. GlobeNewswire: Q4 Results
• Negative Sentiment: Rising short interest — Short interest rose ~41% in February to ~4.0M shares (about 5.1% of float), which increases potential selling pressure and volatility. (Reported data 2/25/2026.)
• Negative Sentiment: Technical/valuation headwinds — Shares are trading below the 50‑day and 200‑day moving averages (50‑day ~$24.08, 200‑day ~$23.13) and nearer the 1‑year low, which can exacerbate downward moves as traders react to the mixed outlook.

Institutional Trading of Progyny

A number of hedge funds have recently made changes to their positions in PGNY. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny in the fourth quarter valued at approximately $25,000. Canada Pension Plan Investment Board bought a new stake in Progyny during the 2nd quarter worth approximately $77,000. Quarry LP grew its holdings in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after acquiring an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Progyny by 203.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock valued at $154,000 after acquiring an additional 4,708 shares during the period. Finally, Entropy Technologies LP bought a new position in shares of Progyny during the fourth quarter valued at $203,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.